Oncotarget

Research Papers:

MicroRNAs of the mir-17~92 cluster regulate multiple aspects of pancreatic tumor development and progression

Brian Quattrochi, Anushree Gulvady, David R. Driscoll, Makoto Sano, David S. Klimstra, Christopher E. Turner and Brian C. Lewis _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:35902-35918. https://doi.org/10.18632/oncotarget.16277

Metrics: PDF 832 views  |   HTML 900 views  |   ?  


Abstract

Brian Quattrochi1, Anushree Gulvady2, David R. Driscoll1, Makoto Sano3, David S. Klimstra4, Christopher E. Turner2, Brian C. Lewis1,5,6

1Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605, USA

2Department of Cell and Developmental Biology, State University of New York Upstate Medical Center, Syracuse, NY 13210, USA

3Division of Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine, Itabashi-ku, Tokyo, 173-8610, Japan

4Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA

5Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA

6Department of Radiation Oncology, University of Massachusetts Medical School, Worcester, MA 01605, USA

Correspondence to:

Brian C. Lewis, email: Brian.Lewis@umassmed.edu

Keywords: pancreatic cancer, mir-17~92, PanIN, regression, invasion

Received: May 30, 2016     Accepted: March 08, 2017     Published: March 16, 2017

ABSTRACT

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy characterized by resistance to currently employed chemotherapeutic approaches. Members of the mir-17~92 cluster of microRNAs (miRNAs) are upregulated in PDAC, but the precise roles of these miRNAs in PDAC are unknown. Using genetically engineered mouse models, we show that loss of mir-17~92 reduces ERK pathway activation downstream of mutant KRAS and promotes the regression of KRASG12D-driven precursor pancreatic intraepithelial neoplasias (PanINs) and their replacement by normal exocrine tissue. In a PDAC model driven by concomitant KRASG12D expression and Trp53 heterozygosity, mir-17~92 deficiency extended the survival of mice that lacked distant metastasis. Moreover, mir-17~92-deficient PDAC cell lines display reduced invasion activity in transwell assays, form fewer invadopodia rosettes than mir-17~92-competent cell lines and are less able to degrade extracellular matrix. Specific inhibition of miR-19 family miRNAs with antagomirs recapitulates these phenotypes, suggesting that miR-19 family miRNAs are important mediators of PDAC cell invasion. Together these data demonstrate an oncogenic role for mir-17~92 at multiple stages of pancreatic tumorigenesis and progression; specifically, they link this miRNA cluster to ERK pathway activation and precursor lesion maintenance in vivo and identify a novel role for miR-19 family miRNAs in promoting cancer cell invasion.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16277